Economic relevance of congestive heart failure. An overview of costs and cost-effectiveness of treatment;Okonomische bedeutung der herzinsuffizienz: Eine ubersicht der kosten und der wirtschaftlichkeit der therapie

Herz

Volumn 25, Issue 5, 2000, Pages 538-546

  Szucs, Thomas D ^b   Sokolovic, Emina ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

Congestive heart failure; Cost of illness; Costs; Pharmacoeconomics

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PLACEBO;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; GERMANY; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MORTALITY; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; REVIEW;

EID: 0033842541     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00001966     Document Type: Review

References (53)

1. A convenient approximation of life expectancy - The DEALE. I. Validation of the method
2. A convenient approximation of life expectancy - The DEALE. II. Use in medical decision-making
3. Effects of the early administration of zofenopril on onset and progression of congestive heart failure in patients with anterior wall acute myocardial infarction. The SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation
4. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis
5. A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia
6. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
7. Effect of vasodilator therapy on mortality in chronic congestive heart failure
8. Cost-effectiveness of carvedilol for heart failure
9. Chronische herzinsuffizienz. Soziookonomische bedeutung in der bundesrepublik Deutschland
10. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure
11. Heart failure: A growing public health problem
12. Overview of randomised trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
13. Quality of life six months after myocardial infarction treated with thrombolytic therapy
14. Costs and effects of enalapril therapy in patients with symptomatic heart failure: An economic analysis of the studies of left ventricular dysfunction (SOLVD) treatment trial
15. National hospital discharge survey
16. The cost effectivenes of enalapril in the treatment of chronic heart failure
17. Incorporating future costs in medical cost-effectiveness analysis: Implications for the cost-effectiveness of the treatment of hypertension
18. Socioeconomic aspects of ACE inhibition in the secondary prevention in cardiovascular diseases
19. Influence of age on the prognostic importance of left ventricular dysfunction and congestive heart failure on long-term survival after acute myocardial infarction
20. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of left ventricular dysfunction investigators
21. How attractive does a new technology have to be to warrant adoption and utilization?
22. A cost-minimization of heart failure therapy with bisoprolol in the French setting: An analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study
23. The natural history of congestive heart failure: The Framingham study
24. Trends in hospitalization for heart failure in Scotland 1980-1990
25. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep venous thrombosis
26. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure
27. Cost-effectiveness analysis in clinical practice
28. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: The studies of left ventricular dysfunction
29. A scale of valuations of states of illness: Is there a social consensus?
30. Wirtschaftlichkeit von bisoprolol bei herzinsuffizienz. Okonomische bewertung der Cardiac Insufficiency Bisoprolol Study (CIBIS) fur die Bundesrepublik Deutschland
31. Heart failure. A decision analytic analysis of New Zealand data using the published results of the SOLVD treatment trial
32. Recommendations on reporting cost-effectiveness analyses
33. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
34. Die soziookonomische evaluation. Einfuhrung in die methodologie
35. Wirtschaftlichkeit der ACE-hemmung in der therapie der chronischen herzinsuffizienz in der Schweiz: Evaluation auf der grundlage der SOLVD-studie
36. Five hundred life-saving interventions and their cost-effectiveness
37. Utilities and quality-adjusted life years
38. Measurement of health state utilities for economic appraisal
39. Stability of time tradeoff utilities in survivors of myocardial infarction
40. Cost-effectiveness of captopril therapy after myocardial infarction
41. Cost-benefit analysis of early thrombolytic treatment with intracoronary streptokinase
42. Kosten-wirksamkeits-analyse der herzinsuffizienz-therapie mit ACE-hemmern am beispiel enalapril
43. Economic outcomes of withdrawal of digoxin therapy in adult patients with stabile congestive heart failure
44. Enalapril: A review of quality-of-life and pharmacoeconomics aspects of its use in heart failure and mild moderate hypertension
45. Changes in hypertension treatment and in congestive heart failure mortality in the United States
46. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients